GH1 and pituitary tumor: Our study supports that the variables linked to resistance to fgSRL in GH&PRL-PAs are similar to those described for pure GH-PAs; thus, the algorithm of personalized medicine is also applicable to these pituitary tumors (20), including the association of fgSRL with cabergoline rather than fgSRL in monotherapy as first-line therapy, especially in the preoperative period (4).